The European Commission has approved Sepalna (senaparib) for maintenance treatment in adults with advanced epithelial high-grade ovarian, fallopian tube, or primary peritoneal cancer who have responded to first-line platinum-based chemotherapy. This approval is specifically for patients with FIGO stage 3 and 4 diseases.
The decision, announced on November 12, 2026, follows a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) in September 2026. This marks a significant regulatory achievement for the treatment in Europe.
Pharmanovia and IMPACT Therapeutics jointly released the news about the authorization, which is applicable across the European Union. Pharmanovia holds exclusive regional development and commercial rights for senaparib in 66 countries, including the UK, Norway, Iceland, Switzerland, Liechtenstein, Australia, New Zealand, and various countries in the Middle East and North Africa.
Senaparib is a targeted anti-cancer therapy developed by IMPACT Therapeutics. The approval is backed by results from the phase 3 FLAMES study, a randomized, double-blind, placebo-controlled trial that included patients diagnosed with advanced ovarian cancer responding to initial platinum-based chemotherapy, irrespective of their BRCA mutation status.
In the study, with a median follow-up of 48.5 months, median progression-free survival was 38.7 months for patients receiving senaparib compared to 13.6 months for those on placebo. The benefits were evident in both BRCA-mutated and BRCA wild-type populations.
Safety data from 403 patients indicated that 5.6% of those treated with senaparib discontinued the treatment due to adverse events. Common adverse effects included anemia, neutropenia, leukopenia, thrombocytopenia, elevated transaminases, weight gain, nausea, and abdominal pain. However, no treatment-related adverse events resulted in fatalities.
Stephan Eder, CEO of Pharmanovia, stated, “The European Commission’s approval of Sepalna represents an important milestone for patients with advanced ovarian cancer and for our growing oncology portfolio.” He further congratulated IMPACT Therapeutics on their achievement, emphasizing the significance of their years of research and clinical development. Eder also noted that Pharmanovia is preparing for the introduction of Sepalna across Europe, aiming to make the treatment available to eligible patients.


